Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

C Zhang, Z Wu, JW Li, H Zhao, GQ Wang - International journal of …, 2020 - Elsevier
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …
被引用次数：2127 相关文章
[PDF] greeninstitute.ng

[PDF][PDF] The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

C Zhang, Z Wu, JW Li, H Zhao, GQ Wang - 2020 - greeninstitute.ng
abstract Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has
swept the world. Although the case fatality rate is not high, the number of people infected is …

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.

C Zhang, Z Wu, JW Li, H Zhao… - International Journal of …, 2020 - europepmc.org
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

C Zhang, Z Wu, JW Li, H Zhao… - International journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …
[PDF] atlasautoinmunidad.org

[PDF][PDF] The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

C Zhang, Z Wu, JW Li, H Zhao, GQ Wang - 2020 - atlasautoinmunidad.org
abstract Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has
swept the world. Although the case fatality rate is not high, the number of people infected is …

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.

C Zhang, Z Wu, JW Li, H Zhao, GQ Wang - 2020 - cabidigitallibrary.org
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …

[引用][C] Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

C Zhang, Z Wu, JW Li, H Zhao, GQ Wang - International Journal of …, 2020 - cir.nii.ac.jp
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab
may be the key to reduce mortality | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
[PDF] dssurgery.com

[PDF][PDF] The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

C Zhang, Z Wu, JW Li, H Zhao, GQ Wang - 2020 - dssurgery.com
abstract Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has
swept the world. Although the case fatality rate is not high, the number of people infected is …
[HTML] nih.gov

[HTML][HTML] Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

C Zhang, Z Wu, JW Li, H Zhao… - International Journal of …, 2020 - ncbi.nlm.nih.gov
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

C Zhang, Z Wu, JW Li, H Zhao… - International journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …